{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-027254","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.477304+00:00","generated_at":"2026-06-14T04:07:55.328546+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Sana Biotechnology 2023 annual meeting results; all director nominees elected, auditor ratified","bullets":["Hans E. Bishop elected Class II director with 108,928,064 votes for, 19,856,165 withheld.","Robert Nelsen elected Class II director with 111,403,976 votes for, 17,380,253 withheld.","Alise S. Reicin, M.D. elected Class II director with 110,664,981 votes for, 18,119,248 withheld.","Ratification of Ernst & Young as auditor for FY2023 approved: 142,770,600 for, 184,749 against, 125,243 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-027254","json":"https://secwatch.observer/filing/0000950170-23-027254.json","markdown":"https://secwatch.observer/filing/0000950170-23-027254.md","text":"https://secwatch.observer/filing/0000950170-23-027254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000095017023027254/0000950170-23-027254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000095017023027254/sana-20230608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:07:55.328546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e0bba78b3860b204d8127502c9e3cf89ad3e2fb","claim":"Sana Biotechnology, Inc. shareholders approved Election of three Class II directors to serve until 2026 at the 2023-06-08 meeting.","evidence_excerpt":"Proposal 1: The Company’s stockholders elected all the nominees to serve as Class II directors of the Company’s Board of Directors, each to serve for a three-year term expiring at the Company’s 2026 annual meeting of stockholders or until his or her respective successor is duly elected and qualified, by the votes set forth in the table below: Nominees For Withheld Broker Non-Votes Hans E. Bishop 108,928,064 19,856,165 14,296,363 Robert Nelsen 111,403,976 17,380,253 14,296,363 Alise S. Reicin, M.D. 110,664,981 18,119,248 14,296,363","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000095017023027254/0000950170-23-027254-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"2440f520fee6eaffff8934a755d523e6b1a43528","claim":"Sana Biotechnology, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-08 meeting.","evidence_excerpt":"Proposal 2: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, by the votes set forth in the table below: For Against Abstain 142,770,600 184,749 125,243","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000095017023027254/0000950170-23-027254-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}